- Home
- MERC vs AGEN Comparison
MERC vs AGEN Comparison
Compare MERC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MERC | AGEN |
|---|---|---|
| Founded | 1968 | 1994 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Paper | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.5M | 126.8M |
| IPO Year | 1987 | 2000 |
Fundamental Metrics
Financial Performance| Metric | MERC | AGEN |
|---|---|---|
| Price | $2.09 | $4.10 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 2 |
| Target Price | $3.00 | ★ $14.50 |
| AVG Volume (30 Days) | ★ 570.2K | 449.8K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 10.82% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,906,971,000.00 | $106,829,000.00 |
| Revenue This Year | N/A | $67.15 |
| Revenue Next Year | $13.78 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.48 | $1.38 |
| 52 Week High | $8.28 | $7.34 |
Technical Indicators
Market Signals| Indicator | MERC | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 59.74 | 47.33 |
| Support Level | $1.78 | $3.92 |
| Resistance Level | $1.95 | $4.13 |
| Average True Range (ATR) | 0.12 | 0.21 |
| MACD | 0.06 | -0.04 |
| Stochastic Oscillator | 89.55 | 32.93 |
Price Performance
Historical ComparisonAbout MERC Mercer International Inc.
Mercer International Inc is a forest products company with two reportable operating segments in pulp and solid wood. The pulp segment consists of the manufacture, sale, and distribution of pulp, electricity, and chemicals. The company has a geographical presence in the USA, Germany, China, and Other countries, where the majority of revenue is generated from the USA. The majority of the revenue is generated from the Pulp segment.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).